출처: Investing.com, 2026-09-25
Barclays upgraded Humana Inc. (NYSE: HUM) from Equal Weight to Overweight and raised its price target sharply from $407 to $515. This bullish revision reflects increased confidence in Humana's upcoming Medicare star ratings, expected to be released on October 8, which could materially enhance the company's contract bonuses and stock performance.
Humana Inc. shares rose 6% Friday after the upgrade, with the stock climbing as much as 9% intraday, marking its largest gain since June. The upgrade was based on "an increasingly constructive view that the company will flip several contracts to bonus status, including H5216, which covers 2.4 million lives."
Barclays가 휴매나를 '중립'에서 '비중확대'로 상향하며 목표가를 407달러에서 515달러로 27% 올렸다. 10월 8일 발표되는 메디케어 별점 반등 기대가 핵심 근거로, 2.4백만 명 가입 H5216 계약 등이 보너스 등급으로 전환될 것이라는 확신이 커졌다. 상향 발표 후 주가는 장중 최대 9% 급등하며 6월 이후 최대 상승폭을 기록했다.
원문: Investing.com